Carlyle Group to acquire 20% stake in Piramal Pharma for $490m
US-based private equity firm Carlyle Group has agreed to acquire a 20% stake in Piramal Pharma, the pharmaceutical business of India-based Piramal Enterprises, in a deal worth up
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XUS-based private equity firm Carlyle Group has agreed to acquire a 20% stake in Piramal Pharma, the pharmaceutical business of India-based Piramal Enterprises, in a deal worth up
Bristol Myers Squibb along with its partner Acceleron Pharma has received the European regulatory approval for Reblozyl (luspatercept) to treat transfusion-dependent anaemia. The European Commission indicated Reblozyl for
Novartis has resolved its Foreign Corrupt Practices Act (FCPA) investigations into historical conduct, through settlements with the US Department of Justice (DOJ) and the US Securities and Exchange
Swedish biopharmaceutical company Hansa Biopharma has received the positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) for Idefirix (imlifidase) to
Sosei Heptares has entered into an exclusive discovery collaboration and option to license agreement with AbbVie to develop advanced small molecules targeting inflammatory and autoimmune diseases. Under the
Merck has secured the US Food and Drug Administration (FDA) approval for KEYTRUDA to treat a type of cutaneous squamous cell carcinoma (cSCC). The US FDA indicated KEYTRUDA
Gilead Sciences has agreed to acquire a 49.9% equity interest and hold an exclusive option to purchase the remaining equity in Pionyr Immunotherapeutics for $275m. Under the terms
Thermo Fisher Scientific has expanded its partnership with Daiichi Sankyo to jointly develop a companion diagnostic (CDx) for its next-generation sequencing (NGS)-based Oncomine Dx Target Test. The CDx
Deciphera Pharmaceuticals has received Health Canada authorisation for Qinlock (ripretinib), a switch-control tyrosine kinase inhibitor designed to treat a type of stomach cancer. The regulatory authorisation indicated Qinlock for
US-based immuno-oncology firm Agenus and China-based Betta Pharmaceuticals have signed an exclusive collaboration and license agreement for balstilimab and zalifrelimab. The licensing agreement allows Betta to develop and